hair loss from glp-1 has increasingly been reported among patients using and GIP agonists for weight loss. These include drugs like semaglutide, tirzepatide, liraglutide and others. Historically, this hair loss has been attributed GLP-1 and Hair Loss: How

Klein notes that, in the trial, GLP-1s appeared to help with opioid addictions in a similar fashion as food addictions, enabling users to better control resisting cravings and ultimately avoid addiction behaviors

Body composition analysis (DEXA or InBody) at 8-week intervals shows preferential loss of truncal fat

The purpose is allowing natural receptor sensitivity restoration and baseline assessment

Health impacts of M

The FDA decision is anticipated in 4Q2025

Sustained, significant weight loss Studies show that people using brand-name tirzepatide for the long term tend to lose a significant amount of weight and keep it off